The series B gives PGDx the means to pursue approvals of its tissue and liquid biopsy IVD cancer tests in markets around the world.

The series D positions Miracor to advance toward approval its device to improve heart function in patients following acute myocardial infarction.

Disclosure of the round comes six months after midphase data positioned Beta Bionics to look forward to a pivotal trial of its diabetes device.

Zimmer Biomet named Bryan Hanson, an executive at rival devicemaker Medtronic, as its new president and chief executive.

The Zoll Medical-led round comes two months after Respicardia secured FDA clearance to market its implantable neurostimulation system.

The series B gives Bigfoot the financial muscle to move its automated insulin infusion device into a pivotal clinical trial in the U.S. next year. 

The technology is designed to support the performance and interpretation of echocardiograms.

Insightec to will use the cash to support commercialization of its noninvasive neurosurgery device and support the expansion into new indications.